View all veterinary jobs
The Yumivet VH2500 measures 57 parameters including Complete Blood Count (CBC) with a 9-part differential, reticulocyte analysis, and dual platelet measurement methods.
The analyser enables open tube or continuous sample loading and includes pre-configured species profiles with automatic selection or easy switching between species.
It also has an intuitive touchscreen interface, a simplified reagent system, and automated quality control features.
The Yumivet VH2500 is compatible with a slide maker and stainer called Yumivet SPS, a track system called Yumizen T6000, and middleware called Yumizen P8000, and offers connection to laboratory and practice management systems (LIS/PMS).
The Yumivet VH2500 is built on a hybrid analytical platform combining electrical impedance, fluorescence, flow cytometry and spectrophotometry, which Horiba says delivers robust and reliable performance across a wide range of sample types, including challenging or low-volume samples.
https://www.horiba.com/int/veterinary/products/detail/action/show/Product/yumivet-vh2500-7004/
Cellular haemoglobin concentration mean gives clinicians a direct measurement of the average haemoglobin concentration within individually analysed red blood cells.
Unlike mean corpuscular haemoglobin concentration, which is a calculated value, cellular haemoglobin concentration mean is measured optically, which Zoetis says provides a more reliable indicator needed when a patient is anaemic and when endogenous interferents, such as haemolysis, are present.
The expansion also includes plateletcrit (PCT) measurement.
Plateletcrit provides the volume percentage of blood occupied by platelets – functionally similar to how haematocrit (HCT) reflects the red blood cell fraction.
Zoetis says PCT helps clinicians better assess platelet production, consumption, and evidence of destruction.
Both new parameters are expected to be available to Vetscan OptiCell users in 2026.
https://www.zoetisdiagnostics.com/uk
The initiative is aimed at increasing screening throughout the year and helping identify cats living with untreated hypertension.
Challenge 20 encourages vet professionals to screen and record over 20 new feline blood pressure measurements per practice in cats at increased risk, including those with concurrent diseases such as chronic kidney disease and hyperthyroidism, those with signs of target organ damage and all cats over seven years of age.
After the feedback session, the Ceva vet will work with the practice to identify any training requirements and create a tailored plan, before repeating the challenge to track progress and fine-tune the approach.
Ceva is also providing marketing materials focusing on hidden hypertension and concurrent disease, including a cat owner poster, leaflet, owner email content and a social media toolkit.
The company is also offering dedicated time and guidance from its territory managers to help implement better screening protocols.
A feline hypertension bitesize video CPD series is also available at the Ceva Academy: https://ceva.vbms-training.co.uk
Andrew Fullerton, senior product manager at Ceva, said: "Over 1,200 cats were screened during Ceva's 2025 feline hypertension campaign and a third of them were identified as hypertensive1."
He added: "We continue to encourage vet professionals to test for feline hypertension in all cats over seven years of age, with a particular focus on those more susceptible to high blood pressure, such as those with concurrent diseases and those with signs of target organ damage through our Challenge 20 initiative."
https://easethepressure.co.uk
Reference
The study was led by Ruby Chang, Associate Professor of Statistics at the RVC, and carried out by Dr Hanya Ahmed.
The team compiled a databank of images, including 100 equine fracture cases from two UK equine hospitals and published literature, alongside 70 feline cases from hospital databases and around 4,000 human fracture images from a public database.
Using these images, the researchers built a three-stage AI system that first identifies the scan type, then recognises the image angle, before detecting and precisely localising fractures.
The system used transfer learning, enabling it to be trained on the large human dataset before being adapted for equine cases.
Using this method, the system achieved a reported fracture localisation accuracy of between 71 and 84% without requiring an unrealistically large number of equine images.
The RVC said the findings demonstrate the potential for AI-assisted tools to strengthen fracture diagnosis across veterinary practice.
It said faster and more reliable detection could reduce uncertainty in clinical decision-making and enable earlier treatment for racehorses and companion animals.
Building on the work, the team has expanded its collaboration with the Hong Kong Jockey Club to investigate whether AI can identify early bone changes before fracture occurs.
The study has been shortlisted for the STEM for Britain 2026 award and was funded by the Horserace Betting Levy Board.
The one-hour session is aimed at veterinary staff undertaking radiography.
It will focus on hands-free techniques, with practical approaches to stable patient positioning and producing consistent, repeatable images without relying on manual restraint or complex setups.
It will also cover will also cover what defines a good radiographic image, using real-life examples such as ‘what a lateral elbow should look like’.
The webinar will include an overview of legal obligations around ionising radiation.
The session will be presented by VET.CT radiologist Dr Lisa Friling (pictured), who said: "Improving radiation safety in practice does require change, which can be challenging.
"However, this change is important - to improve health and welfare of patients and the safety of staff, and it is absolutely possible with the right support and guidance.”
The recording will be added to VET.CT’s free X-Pert Radiation Safety Centre, which includes downloadable toolkits for small animal and equine practice, including positioning guides, top tips, chemical restraint protocols and case studies.
Morning registration: https://events.zoom.us/ev/AoUvrzk-_2uzZnp4qAmFOGXmRcK1aTTw-6qvuXG9dcE1R9P6nekq~Anw9-XhUxtsFzbNTgw72jB-z7T3VYWaNeeenRj7ewgvpDl2-SZXIsQQCoA Evening registration: https://events.zoom.us/ev/AhNUeTTJeRFdCzhNTqhFXC51TVI4oiPcHToPFDrNJGeKzxSD9KjG~As1a8XpiRKr-QcSd8p2-ki8MyicKNFrSRGNG8ZTRBTLssfxmt46S5Xfv9Q
The X-Pert radiation safety resources for small animal practice: https://uk.vet-ct.com/welcome-to-x-pertEquine resources here: https://uk.vet-ct.com/welcome-to-x-pert-equine
Although feeding tubes are widely used in practice, there has previously been no agreed radiographic criteria to confirm correct positioning, creating uncertainty and increasing the risk of serious complications such as aspiration pneumonia and pneumothorax.
The new guidelines address this gap by providing an evidence-based framework for interpreting lateral neck and thoracic radiographs.
Led by Andrea Vila Cabaleiro, Small Animal Diagnostic Imaging Resident at the RVC, the research team collected 256 lateral neck and chest radiographs of dogs and cats with nasoesophageal or nasogastric feeding tubes in place.
The images were sourced from ten private and academic institutions, including the RVC’s Queen Mother Hospital for Animals.
Expert veterinary radiologists then verified whether the tubes were correctly placed in the oesophagus (food pipe) or incorrectly in the trachea (windpipe).
From this dataset, the researchers developed a simple three-point radiographic checklist to confirm correct tube placement:
To assess the clinical value of the guidelines, six veterinarians with varying levels of experience reviewed the same radiographs on two occasions, first using their usual judgement and then, after a minimum seven-day interval, using the new guidelines. Diagnostic accuracy improved from 82% to 96%, while uncertainty fell from 14% to 2%. Inter-observer agreement also improved from moderate to almost perfect.
The guidelines performed consistently across dogs and cats, a wide range of patient sizes and multiple clinical settings.
The authors concluded that this structured, evidence-based approach improves both accuracy and confidence without requiring additional equipment, making it suitable for use in general practice, referral hospitals and emergency and critical care environments.
An accompanying step-by-step infographic has been produced to support uptake of the guidelines in day-to-day clinical practice: https://www.rvc.ac.uk/Media/Default/VetCompass/260105%20RVC%20Infographic%20-%20Radiographic%20guidelines%20on%20feeding%20tube%20placment.pdf
Vista IQ is designed for non-invasive screening of dermal and subcutaneous masses commonly seen in veterinary practice.
Building on the original HT Vista, Vista iQ retains the same Heat Diffusion Imaging (HDI) technology.
The new device features faster calibration, improved imaging resolution and Wi-Fi connectivity to tablets and smartphones.
HT Vet says Vista iQ has been designed with clinical workflow in mind, with an ergonomic design, full portability and multi-user functionality intended to support use during routine consultations.
Updates include a redesigned user interface for faster navigation, improved light and vibration indicators for real-time feedback, and built-in precision tools including a laser grid and accelerometer for accurate measurements.
Alongside the device, the Vista iQ application includes enhanced case documentation features, allowing clinicians to record mass characteristics, case histories, diagnostics and treatment plans within a single system.
HT Vet has confirmed that the original HT Vista device will be discontinued, with future development focused on Vista iQ.
Practices currently using the original device will continue to receive full technical support.
https://ht-vet.com
The company makes GIQuest, a patient-side lateral flow faecal calprotectin test, which it says can be used to guide next steps in dogs and cats with chronic GI conditions, including chronic enteropathy (CE; previously IBD), food responsive enteropathy (FRE) and GI side-effects associated with NSAID use.
Carus says that a validation study conducted at the University of Bristol has shown that its GIQuest can reliably distinguish dogs and cats with inflammatory enteropathy from healthy controls, with high sensitivity and specificity.
The company says faecal calprotectin is already well established in human medicine as a non-invasive marker of intestinal inflammation and is increasingly being adopted in veterinary practice to support diagnostic decision-making and treatment monitoring.
Lucy Williams MRCVS, from Carus Animal Health, said: “Individual case experiences often highlight nuances that don’t always come through in formal studies.
"Bringing these together can help illustrate how faecal calprotectin testing is being applied in different clinical scenarios, from refining diagnostic pathways to supporting monitoring and owner communication.
"By sharing practical insights from everyday cases, the profession can collectively build confidence around when and how this tool is most useful in practice.”
Case studies can be submitted by both veterinary surgeons and veterinary nurses and may include, but are not limited to: dogs or cats with chronic or recurrent GI signs, suspected inflammatory enteropathies, monitoring response to dietary or treatment trials or identification of GI inflammation in patients receiving long term oral NSAIDs.
As a thank you for taking part, the five strongest submissions will each receive a £100 gift card, and the first 20 eligible entries will receive free access to a GI-focused CPD course with The Webinar Vet.
In addition, entries submitted before 31st January will be entered into a draw to win a delegate ticket to SPVS Congress (Birmingham, 26–27th February), worth £675.
Entries close on 1st March.
Further information and case study form/guidelines available here: https://carusanimalhealth.com/giquest/prizes
https://carusanimalhealth.com/giquest
Vidas Equine Insulin provides insulin levels in approximately 20 minutes, which the company says will help with the diagnosis and management of Equine Metabolic Syndrome (EMS), commonly associated with insulin dysregulation in horses.
Vidas Equine ACTH provides dysregulation level testing of the adrenocorticotropic (ACTH) hormone related to the development of Equine Cushing’s Disease (aka Pituitary Pars Intermedia Dysfunction - PPID) in about 45 minutes.
Pierre Rouppert, Global Veterinary Product Manager at bioMérieux, said: “Our new endocrinology tests, because of their rapidity and ease of use, will bring clinical value for veterinary practices, directly at the Point of Care.
"Equine Metabolic Syndrome and Cushing’s Disease are chronic conditions that often evade detection in their initial stages, making early testing crucial in achieving proper management and animal care.”
David Smart, Global Veterinary Business Developer at bioMérieux, said: “This dedicated equine immunoassay test for insulin and ACTH represents a transformative step forward in animal care.
"Veterinary practitioners will be able to achieve fast, reliable and cost-effective laboratory grade results that can aid early detection and subsequent diagnosis for two prolific and debilitating medical conditions in horses.
"The fast and accurate results from these two new tests will allow quicker clinical decisions that will ultimately help more horses receive an improved standard of care and reassure horse owners.”
https://www.biomerieux.com/corp/en/our-offer/clinical-products/vidas-equine-insulin.html
Camilla, who was shortlisted as a finalist for Innovator of the Year at the 2025 Digital Women Awards, says her mission has always been to give first-opinion vets the tools and confidence to get the most from ultrasound in everyday practice – and the new tool is a big step forward in that vision.
The tool:
Camilla says the final report is fully editable, but much of the “heavy lifting” is done — saving time, reducing second-guessing, and producing reports that are more useful for colleagues, clients, and patient care.
https://www.fovu.co.uk/
https://www.fovu.co.uk/fovu-report-video
This, says the company, highlights a missed opportunity for earlier cancer detection, which in turn limits the ability of veterinary teams to improve medical outcomes for their patients.
243 veterinary professionals took part in the survey, most of whom HT Vista says were general practitioners.
On average, they reported seeing 13.5 dermal and subcutaneous masses per vet per week, less than six of which lead to a diagnosis.
HT Vista says around 15% of these lumps will be malignant.
Veterinary oncologist Gillian Dank said: “Every week, thousands of dogs leave practices with undiagnosed masses.
"While many are benign, others are malignant, and delaying diagnosis can mean lost treatment opportunities and poorer prognoses.”
The number one reason why respondents said they don't test more widely is the assumption that a mass is benign by its gross characteristics, followed by owner concerns around cost, time constraints during consultations, and limited access to in-house cytology.
Vista HT Chief Commercial Officer Asher Fink and Managing Director Liron Levy-Hirsch will be presenting “20 dogs in your waiting room with lumps and bumps – how do you spot the 3 with cancer?" at the London Vet Show on 20th November from 1–1:50pm in Exhibitor Showcase Theatre 2
https://info.ht-vet.com/lump-and-bump-survey-results
https://www.cliniciansbrief.com/continuing-education/syllabus/lesson/cracking-code-lumps-bumps-fast-efficient-diagnosis-everyday-practice
https://london.vetshow.com/conference-programme-2025/session-title-coming-soon-38
Photo: www.depositphotos.com
Zoetis says AI Masses delivers fast, accurate, in-clinic screening of common lymph node and skin/subcutaneous masses in minutes, making Vetscan Imagyst the most capable veterinary AI analyser in the world.
AI Masses uses an algorithm to identify and classify common skin/subcutaneous mass and lymph node aspirates at the point of care.
At additional charge, for added diagnostic confidence, Zoetis also offers expert clinical pathologist reviews via Digital Cytology and Add-on Expert Review within hours.
Abhay Nayak, President, Global Diagnostics at Zoetis said: “By empowering veterinary teams with valuable insights into potentially cancerous cells, we are helping to reduce waiting times and alleviate stress for pet owners facing some of the most challenging moments with their beloved pets.
https://www.zoetisdiagnostics.com/uk/point-of-care
Faecal calprotectin is a calcium-binding protein released into the gut lumen predominantly by neutrophils, and to a lesser extent by monocytes and macrophages, during intestinal inflammation.
Its presence in faeces reflects the degree of neutrophilic infiltration in the gut mucosa, making it a useful biomarker for identifying intestinal inflammation.
Faecal calprotectin lateral flow testing is already used in human health and included in the NICE guidelines for the management of inflammatory bowel disease (IBD)1.
Determining the underlying cause of chronic diarrhoea, vomiting and weight loss in cats and dogs can be complex, often requiring invasive procedures such as endoscopy or biopsy - both of which carry cost, risk, and sometimes practical limitations in general practice.
GIQuest is designed to offer a non-invasive, rapid alternative to support clinical decision-making.
Carus says that whilst not a replacement for histopathology, faecal calprotectin concentrations have been shown to correlate with disease severity in dogs and cats, as measured by tools such as the Canine Chronic Enteropathy Clinical Activity Index (CCECAI).2
New data from the University of Bristol Vet School appears to confirm the test’s ability to differentiate dogs with histologically-confirmed inflammatory enteropathy from healthy controls with high sensitivity (94%) and specificity (96%) using a score threshold of 3mg/kg.2
Carus says the test also performed well in cats, distinguishing those with inflammatory enteropathy from healthy controls with a specificity of 100% and sensitivity of 92%.
In addition, the test detected elevated calprotectin levels consistent with inflammatory gastroenteropathy in 25% of dogs receiving oral NSAIDs, which highlights its potential not only in long-term monitoring but also early in treatment when GI side effects may first emerge.
Jolian Howell of Carus Animal Health said: “Faecal calprotectin testing can provide additional clarity in a range of clinical scenarios.
"It is particularly useful when diagnosing and managing suspected inflammatory enteropathy or food related reactions and for monitoring or screening for GI side effects of oral non-steroidal anti-inflammatories in long term OA therapy regimes.”
The Bristol study also showed that dogs with food-responsive enteropathy had a significant drop in calprotectin concentrations following dietary change, reinforcing the test’s role in tracking treatment response.
Georgie Louca, Veterinary Business Manager for Carus Animal Health, added: ”By providing a measurable, visual indicator of intestinal inflammation, GIQuest also helps support client communication and can improve compliance during treatment or dietary trials.”
GIQuest is designed for use in practice, including during consultations, delivering colour-coded results in 15 minutes.
GIQuest is now available to veterinary practices across the UK and can be ordered through veterinary wholesalers NVS, Covetrus and MWI.
References
The new Tosoh AIA 900 analysers have been trialled for the last 18 months at Liphook Equine Hospital, which was the first practice to introduce ACTH testing for horses 25 years ago and gets hundreds of blood samples every week from veterinary practices all over the UK and Europe.
Professor Andy Durham, who heads up the laboratory at Liphook, said the test period has shown that the new machine produces more accurate results primarily because it’s less sensitive to ACTH degrading in blood samples between collection and receipt by the laboratory.
Andy said: “There are several analytic methods available for use in horses, and we wanted to see if this alternative machine had diagnostic benefits over the ones we’d used previously.
"The ACTH molecule we test for immediately begins to break down after a blood sample is taken, even if you handle it carefully and place it in chilled packaging, but this new analyser is able to detect much more of the degraded ACTH molecule, and therefore it gives a more accurate result.
“As a comparison, ACTH values measured using the previous method suffered about three to four times more degradation over 24 hours.
"What this means for horse owners is that it will reduce the risk of false negative results in ACTH tests, so more horses suffering from Cushing’s disease will receive the treatment they need.”
In testing, the new analysers also demonstrated greater accuracy when measuring insulin levels in blood samples.
https://liphookequinehospital.co.ukhttps://www.rainbowequinehospital.co.uk https://www.rossdales.com
Biomérieux says the new test, which is used on the Biofire Spotfire System, detects seven infectious respiratory pathogens (six viruses and/or a strain of bacteria*), from a nasopharyngeal swab, in under 20 minutes.
The company says the new test’s ability to distinguish between viral and bacterial infections is important for ensuring antibiotics are used appropriately to reduce the risk of resistance.
Biomérieux says VetFire can be used to make informed decisions about when to isolate and treat animals when respiratory infections are suspected, to mitigate the impact of an outbreak in a contained area, such as a yard, by allowing rapid quarantine measures, and perhaps in time as a standard test ahead of animals travelling for competition, to ensure they are fit and healthy.
VetFire is commercially available in United Kingdom, Ireland and France, with possible expansion plans to other countries in the near future.
https://www.biomerieux.com/corp/en/our-offer/clinical-products/vetfire.html
*Equine Herpesvirus type 1, Equine Herpesvirus type 4, Influenza A, Equine Rhinovirus A, Equine Rhinovirus B, Equine Adenovirus 1, Streptococcus equi equi
The update includes a new scoring system of low, moderate or high cancer risk which replaces the original numerical HDI scores and simplifies interpretation for clinicians, making the screening process easier to communicate with pet owners.
HT Vista says the device can now categorise cancer risk levels, based on malignant probability, with a sensitivity of 90% and a negative predictive value (NPV) of 98%.
The company says this translates to a “low cancer risk” result having a malignant probability of 10% or less, allowing veterinary teams to rule out cancer of lumps and bumps without the need for invasive procedures.
The tool can also now provide alerts for some of the low-risk cases, identifying them as lipomas, sebaceus adenomas or benign epithelial masses.
Liron Levy-Hirsch DVM MRCVS, Managing Director at HT Vista, said: "I am incredibly excited to enhance our already powerful HT Vista screening tool with a new diagnostic capability, providing veterinary teams with an even more comprehensive decision-support system.
"Our screening technology has already been a game-changer in early detection, and now, with the ability to flag specific tumour types, we are taking another significant step forward.
"This advancement empowers veterinary professionals to make even more informed decisions, supports shared decision-making with pet owners, and ultimately improves patient outcomes.
"By reducing the time from suspicion to diagnosis and treatment, we can detect cancer earlier, avoid the ‘wait and see’ approach, and help save more lives."
On the other end of the scale, a “high cancer risk” result has a malignant probability of 50% or more and indicates a stronger likelihood of malignancy.
HT Vista says these cases require additional diagnostic tests for mass identification.
The company highlights a big distinction between this and other screening modalities is that it can be nurse-led.
HT Vista will be on display and there will be live demonstrations at BSAVA Congress from the 20th to the 22nd of March 2025.
https://bit.ly/ht-vista-screening-tool
The company says AI Masses will allow veterinary professionals to analyse lesions suggestive of cancer in-clinic and with a fast turnaround.
The AI technology, which has been trained by human clinical pathologists, should enable individualised treatment outcomes earlier for more cases.
Zoetis says AI Masses only needs a single round of sample preparation and the results can, at additional cost, be supplemented with an expert review from a network of specialists through Zoetis’ Virtual Laboratory.
Dr. Richard Goldstein, DVM, DACVIM, DECVIM-CA, Global Chief Medical Officer at Zoetis said: “Waiting for results can be stressful for pet owners – even more so when it involves a cancer screening.
"Our research shows that up to 75% of pet owners find abnormal results highly stressful.1
"AI Masses is yet another point-of-care capability to deliver results in-clinic, further exemplifies Zoetis’ purpose to advance care for animals, shortening anxious wait times to allow for faster care decisions that help provide the best possible outcome.”
Pre-orders will be announced for US customers in Q2 2025.
VetSurgeon.org understands AI Masses will be coming to the UK some time in 2025.
https://www.zoetisdiagnostics.com
To date most of these imaging procedures have been performed by vets within the group’s small animal first opinion veterinary practices.
The company says its Foundations in Diagnostic Imaging for Nurses training is designed to give its nurses more clinical stature in first opinion practice.
The programme will teach nurses the workings of an x-ray machine, common X-ray positions and contrast material.
It will also cover the principles of CT and MRI, showing how to set up and operate each piece of equipment, and how to support patients through these imaging procedures.
Finally, the course will provide the training nurses need to be able to perform ultrasounds within the current RCVS legal frameworks.
CVS says it believes this is a first in the veterinary profession
Tara Ryan, Chief Veterinary Nursing Officer at CVS said: “Imaging is a brand new area that we are starting to delegate to our nurses. Having heavily invested in our small animal first opinion practices over the last decade, we have a wide range of imaging equipment at many of our sites.
“Excitingly, this programme will open up the ability for nurses to start to contribute more information - to help vets identify and diagnose conditions and diseases in patients.
"It is another big step that we are taking to empower our brilliant nurses and to enable them to make a great clinical contribution towards the care of our patients – and to be the nurses they want to be.”
CVS is prioritising the consulting room and Schedule 3 delegated tasks as important areas for improving what it calls 'nurse optimisation'.
The company recognises that 'buy in' from veterinary surgeons is vital to the success of its efforts to optimise the role of its nurses, and the group has also published guidelines to provide clarity around effective delegation under Schedule 3.
Ki-67 is a proliferation marker used for assessing tumour aggressiveness, however the traditional method of assessing Ki-67 scores involves manually counting the proliferating cells, which is subjective, time-consuming and prone to variability.
Finn says its new AI-assisted Ki-67 scoring test represents a significant advancement in veterinary diagnostic oncopathology.
The AI algorithm analyses Ki-67 labelling across the entire section of tumour.
Positively labelled cells are highlighted, scores are calculated, and the results are validated by a pathologist before reporting.
This more automated analysis enables the evaluation of large volumes of histological data, ensuring consistent and reliable prognostic assessments.
Finn says it also removes the subjectivity and variability associated with identifying areas of highest cell proliferation, which is a crucial aspect of tumour scoring.
https://www.finnpathologists.com
The company has created the X-Pert Radiation Safety Centre, with free downloadable toolkits for both small animal and equine practice, including positioning guides, top tips, chemical restraint protocols, and a series of case studies with equine and small animal clinics, including Pennard Vets.
Dr Victoria Johnson, CEO and radiologist (pictured), said: “Radiation safety breaches represent a significant health and safety incident and a risk to the health of veterinary team members and their patients.
"Despite this, we know that breaches are not uncommon in clinical practice.
"To help meet the challenge of improving safety in busy practice workflows, VET.CT has created a comprehensive suite of practical resources to support veterinary teams in applying best practice to ensure the health of their personnel and patients.
"We have also partnered with clinics from around the world, including GP, equine and specialist hospitals, to provide some great case studies of how the principles can be applied in practice.”
Victoria added: “Good radiation safety practice also encourages habits that lead to better diagnostics.
"We know that taking extra care to ensure good patient preparation, positioning and optimising settings results in fewer exposures and higher quality diagnostic images for more accurate interpretation.
"This all contributes to improved efficiency, patient management and outcomes, greater satisfaction, and of course, happier owners.”
The X-Pert radiation safety resources for small animal practice: https://uk.vet-ct.com/welcome-to-x-pert
The X-Pert radiation safety resources for equine practice here: https://uk.vet-ct.com/welcome-to-x-pert-equine
Zoetis says the Vetscan OptiCell represents a significant leap forward in technology and offers meaningful time, cost and space savings for veterinary healthcare teams, contributing to better patient outcomes and a more efficient clinic workflow.
It uses cell-focusing and AI-powered classification technology for CBC analysis, delivering a claimed lab quality accuracy at the point of care.
Dr. Richard Goldstein, DVM, DACVIM, DECVIM-CA, Global Chief Medical Officer and Head of Medical Affairs at Zoetis said: “Vetscan OptiCell delivers high-quality results, enables improved efficiency, and provides a compact footprint.
"For the first time, we are able to use advanced AI image recognition technology to characterise the blood cells instead of relying on their size or other physical parameters.”
Pre-orders will be available in the UK later this year.
According to the NFU, last year farm animals worth an estimated £2.4 million pounds were severely injured or killed by dog attacks last year.
Obtaining forensic samples after an attack can be difficult because so often they happen in remote places and rural police can't always attend quickly enough to get a sample.
Dr. Nick Dawnay from Liverpool John Moores University therefore developed Early Evidence Kits to enable samples to be collected by vets, famers and police from the crime scene immediately.
Following a successful proof of concept in Wales, the research team is now trialling the kits in ten regions of England and Wales, with support from IVC Evidensia farm practices.
Over the next twelve months the trial will refine best practices for collecting forensic samples from livestock attack scenes.
David Martin, Group Head of Animal Welfare at IVC Evidensia said: “This project marks an exciting step forward in collecting and analysing canine DNA from livestock.
"It offers police and farmers a means to hold irresponsible dog owners culpable for the damage and losses caused by their pets.”
“As a profession we can support this research by ensuring samples are taken from as many cases within the relevant force areas as possible so that the team at John Moores gets sufficient material to be able to complete this project as soon as possible.
"All IVC Evidensia farm practices in the participating regions are being encouraged to use the kits and we want to ensure all farm practices in those regions know about this important project.”
It is hoped new legislation for England and Wales will be brought in to give police officers the power to take a DNA sample from a suspected dog to compare to canine DNA left at an attack scene.
Dave Allen, North Wales Police and NPCC Livestock Offence Working Group Secretary said: “These kits are an exciting development and can be utilised for an issue that causes major concern to our UK rural communities”.
Veterinary practices are now being encouraged help raise awareness of the project, particularly to encourage farmers to take part and use the kits to collect evidence in the following regions:
https://www.ljmu.ac.uk/about-us/news/articles/2024/5/17/forensic-science-to-help-farmers-foil-sheep-attacks
Charlie says that uniquely, the company offers feedback about samples submitted, with the aim of teaching veterinary staff the skills needed to interpret future samples themselves.
Cytovet is aimed at nurses and new grads who want to improve their cytology skills, vets who don’t have time to look at their own samples or have a tricky case they would like an additional opinion on, and those vets whose clients can’t afford the prices the big labs quote.
Charlie said: "I’m a vet with 16 years of clinical experience and a certAVP which focussed on small animal medicine and clinical pathology.
"I currently work in first opinion charity practice and have examined thousands of cytology samples over the years.
"I have been writing cytology reports for the practices I have worked for since 2012.
"I believe all vets and nurses should have the basic microscope skills required to help make more informed decisions for their patients, particularly in a world of escalating veterinary costs and antimicrobial resistance.
"I can examine both digital images and posted slides using a top-of-the-range trinocular digital microscope.
"All you need to do is submit the patient information and slides to me (digital images or actual slides) via my website and I will provide you with a report within 3-5 days."
Urgent turnaround is also available.
www.cytovet.co.uk
The project was 'highly commended' at the RCVS Knowledge 2024 awards.
The CVS clinical improvement project found that a major barrier to conducting ultrasound scans was a lack of confidence - both in using equipment and interpreting images.
A recent Canadian industry study has also reviewed barriers, citing a lack of equipment, training and skills as root causes1.
The ultrasound project aimed to review practice equipment, improve clinician case identification, increase clinical skills and confidence, and recommend ultrasound in all appropriate cases.
The company put together resources for vets and nurses designed to help improve ultrasound scan rates, including clinical guidelines, webinars for how to approach cases, and machine guides.
CVS then held training sessions which for vets focussed on case identification and improving diagnostic skills, and for vet nurses looked at how to use ultrasound equipment and conduct scans.
An audit of each participating practices’ ultrasound scan rates was conducted at the start of the project. Results were then shared with each practice every month.
Twelve months after launch, data shows that the number of ultrasound scans has increased by 3,675.
Anecdotal evidence has also shown that colleague confidence and practice team culture has improved as a result of the project.
Dr Victoria Woods, Regional Clinical Lead at CVS responsible for the ultrasound clinical improvement project, said: “It’s fantastic to see the benefits increased ultrasonography is already bringing to our practices on this project – especially as a result of upskilling our nurses.
"I am certain that this will help contribute towards them providing some of the best clinical diagnosis and care in our profession.”
Following the success of the project in its first year, the project is now being developed to focus on echocardiograph and is being undertaken in 52 CVS primary care practices in year two.
For the project, the company has developed a Brachycephalic Obstructive Airway Syndrome (BOAS) clinical assessment tool which can be used by a vet or nurse in practice to make a diagnosis.
The assessment is a holistic one which includes taking a history of the animal, a full physical examination, an exercise test and an examination of the dog’s nostrils.
The results of the assessment are then discussed with the owner to agree on a course of treatment.
During each consultation, vets and nurses also look to talk sensitively with clients about breeding, buying and owning brachycephalic dog breeds, offering welfare advice on how to manage their dog’s lifestyle, including issues such as keeping their weight low and looking after them in hot weather.
CVS says it hopes this will increase a general level of welfare awareness amongst brachycephalic dog owners.
CVS has also created a collection of resources for its teams, including new clinical frameworks and veterinary guidelines, webinars and a CPD day on the subject.
The company has also created materials to help vets and nurses have what can be challenging discussions with clients, including consultation room posters and practice reception TV videos which showing the physiology of the brachycephalic breed.
CVS says that since launch in July last year, the 25 participating practices have conducted nearly 900 brachycephalic assessments, and it aims to have at least 5% of Pugs, French Bulldogs and Bulldogs undergoing assessment across its small animal division by 2028.